Endocrine Abstracts

Two anti-CD-20 radioantibody therapies: Y-90 ibritumomab tiuxetan (Zevalin) and I-131 tositutumomab (Bexxar) were approved in the USA in the early 2000s. The safety and efficacy of both Bexxar and Zevalin were proven relative to rituximab. While Zevalin remains on the market, sales are reportedly low. Bexxar exited the market in 2014 after low sales. Bexxar cost $26K USD, ‘very expensive’ by early 21st century standards, but low compared to cancer therapies in 2016. ...